PD-L1 as a biomarker of response to immune-checkpoint inhibitors

Deborah B. Doroshow; Sheena Bhalla; Mary Beth Beasley; Lynette M. Sholl; Keith M. Kerr; Sacha Gnjatic; Ignacio I. Wistuba; David L. Rimm; Ming‐Sound Tsao; Fred R. Hirsch

doi:10.1038/s41571-021-00473-5

Keywords

MedicineBiomarkerConcordanceBiomarker discoveryOncologyCompanion diagnosticImmune checkpointClinical trialPD-L1CancerDiseaseInternal medicineImmunotherapyBioinformaticsBiologyProteomics

Affiliated Institutions

Related Publications

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

Timothy A. Chan , Mark Yarchoan , Elizabeth M. Jaffee +4 more

Abstract Background Treatment with immune checkpoint blockade (ICB) with agents such as anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/...

2018 Annals of Oncology 2769 citations

Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

Hira Rizvi , Francisco Sánchez-Vega , Konnor La +29 more

Purpose Treatment of advanced non–small-cell lung cancer with immune checkpoint inhibitors (ICIs) is characterized by durable responses and improved survival in a subset of pati...

2018 Journal of Clinical Oncology 1371 citations

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

Jun Gong , Alex Chehrazi‐Raffle , Srikanth Reddi +1 more

Early preclinical evidence provided the rationale for programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) blockade as a potential form of cancer immunotherapy g...

2018 Journal for ImmunoTherapy of Cancer 1280 citations

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

Judith A. Seidel , Atsushi Otsuka , Kenji Kabashima

Melanoma, a skin cancer associated with high mortality rates, is highly radio- and chemotherapy resistant but can also be very immunogenic. These circumstances have led to a rec...

2018 Frontiers in Oncology 1279 citations

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Andreas D. Hartkopf , Florin‐Andrei Taran , Markus Wallwiener +4 more

Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-...

2016 Breast Care 30893 citations

Publication Info

Year: 2021
Type: review
Volume: 18
Issue: 6
Pages: 345-362
Citations: 1397
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1397

OpenAlex

Cite This

APA Style

                            
                                
                                    Deborah B. Doroshow, 
                                
                                    Sheena Bhalla, 
                                
                                    Mary Beth Beasley
                                
                                et al.
                            
                            (2021). 
                            PD-L1 as a biomarker of response to immune-checkpoint inhibitors. 
                            Nature Reviews Clinical Oncology
                            , 18
                            (6)
                            , 345-362.
                            https://doi.org/10.1038/s41571-021-00473-5
                        

Identifiers

DOI: 10.1038/s41571-021-00473-5